Brain wave study seeks clues to social anxiety
NCT ID NCT03821779
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This study looks at whether certain slow brain waves in the prefrontal cortex can be a sign of social anxiety. Researchers will measure brain activity in 30 people with social anxiety disorder while they wait to give a speech. The goal is to better understand the brain's role in anxiety, not to test a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
20 people
The number who actually took part.
- Started
-
Nov 2019
- Finished
-
May 2026
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 50 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Social anxiety disorder as defined in DSM-5 * Full understanding of the protocol * Obtaining informed consent from study subjects before or at inclusion at the latest * Being registered in the french national health insurance service (Sécurité Sociale) (or equivalent) Exclusion Criteria: * Active medical co-morbidity including severe hypertension, cardiac insufficiency, Raynaud syndrome, diabetes mellitus, renal insufficiency, adrenal insufficiency, Cushing syndrome and epilepsy * Severe neurological co-morbidity, including but not limited to Parkinson's disease and multiple sclerosis * Long-term corticotherapy * History of significant head injury, defined by loss of consciousness * Being diagnosed with another major psychiatric condition (DSM5) including bipolar disorder and schizophrenia or substance/alcohol use disorder; with the exception of major depressive disorder and nicotine use disorder * Suicidal risk evaluated as moderate to high in the MINI questionnaire * initiation of a psychotropic treatment or change in the dose of ongoing psychotropic treatment within 3 days prior to each visit and including: 1. antidepressant treatments with selective serotonin recapture inhibitors, serotonin and norepinephrine inhibitors, alpha2-presynaptic adrenoreceptors (mirtazapine, mianserin), tricyclic 2. anxiolytic drugs including benzodiazepines and anti-histamine 3. antipsychotic drugs * Acute alcohol intake 2 days prior to each visit (inclusion, experimental sessions) * Pregnancy or breastfeeding. * Ongoing hospitalization without consent (decision of a third-party: medical, justice)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anxiety are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GENPHASS, SANPSY, CHU de Bordeaux
Bordeaux, 33076, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can video games calm anxious teens?
- Can a group program teach teens to cope before therapy starts?
- Could a Patient's playlist take the sting out of nerve testing?
- Three spanish group sessions put a neuroscience twist on anxiety therapy
- Can a rewired EMDR therapy ease the mental toll of migration?
- Classical music vs. anxiety: a simple test in the eye clinic